Protocol summary

Study aim
General goal Use of Cucumis melo L seeds in the treatment of lower urinary tract symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)
Design
Clinical trial with control group, with parallel groups, double-blind, randomized, phase 2 on 80 patients.
Settings and conduct
This study is a prospective human clinical trial ,that will be done ,on 80 men with benign prostatic hyperplasia (BPH) in the age group of 45 to 75 years, who referred to Hasheminejad Hospital clinic and had symptoms of lower urinary tract symptoms (LUTS).
Participants/Inclusion and exclusion criteria
Inclusion criteria All patients aged 45 to 75 years with BPH, including at least one of the following, have an International Score of Prostate Symptoms (IPSS) greater than 13 at screening, a PSA greater than 3 ng / ml, and a prostate volume greater than 30 mm. Cube diagnosed by ultrasound, and patients who are able and willing to sign written consent. Exclusion criteria Surgery, infection, lower urinary tract disease (bladder stones, neurogenic bladder, bladder malignancy, urethral stricture, hematuria), Diabetes, Heart disease (heart failure, MI, unstable angina), uncontrolled hepato-renal disease, use of effective drugs Bladder and prostate (anticholinergics, sympathomimetics, antidepressants) Patients who are unable to use oral medication. Perform any drug intervention simultaneously. Allergy to medicinal plants.
Intervention groups
Intervention group: Will received Tamsulosin (0.4 mg per night, 1 piece) with Cucumis melo L seeds 500 mg oral capsule three times daily after each meal for up to 6 weeks. The medicine is made by a pharmacist. The control group received Tamsulosin (0.4 mg 1 per night) with placebo oral capsules (500 mg of starch) three times daily after each meal for up to 6 weeks.
Main outcome variables
Patients' urinary symptoms

General information

Reason for update
Acronym
BPH
IRCT registration information
IRCT registration number: IRCT20180712040446N3
Registration date: 2022-03-07, 1400/12/16
Registration timing: prospective

Last update: 2022-03-07, 1400/12/16
Update count: 0
Registration date
2022-03-07, 1400/12/16
Registrant information
Name
Atefe Sharif
Name of organization / entity
Country
Iran (Islamic Republic of)
Phone
+98 21 2247 3630
Email address
atf.sharif@sbmu.ac.ir
Recruitment status
Recruitment complete
Funding source
Expected recruitment start date
2022-03-21, 1401/01/01
Expected recruitment end date
2022-11-21, 1401/08/30
Actual recruitment start date
empty
Actual recruitment end date
empty
Trial completion date
empty
Scientific title
Comparison the effect of Cucumis Melo L seeds oral product and Tamsulosin with Tamsulosin and placebo in reducing the symptoms of patients with benign prostatic hypertrophy.
Public title
Effect of Cucumis Melo L seeds on patients with benign prostatic hypertrophy
Purpose
Treatment
Inclusion/Exclusion criteria
Inclusion criteria:
All patients aged 45 to 75 years with BPH who include at least one of the following: International Score of Prostate Symptoms (IPSS) over 13 at the time of screening PSA higher than 3 ng / ml. Prostate volume greater than 30 mm detected by ultrasound Patients who are able and willing to sign a written consent.
Exclusion criteria:
Surgery, infection, lower urinary tract disease (bladder stones, neurogenic bladder, bladder malignancy, urethral stricture, hematuria Gross) Diabetes, Heart disease (heart failure, MI, unstable angina), Hepato-renal disease Use of drugs affecting the bladder and prostate (anticholinergics, sympathomimetics, antidepressants) Patients who are unable to use oral medication. Participate in concurrent drug intervention. Allergy to medicinal plants.
Age
From 45 years old to 75 years old
Gender
Male
Phase
3
Groups that have been masked
  • Participant
  • Care provider
  • Data analyser
Sample size
Target sample size: 80
Randomization (investigator's opinion)
Randomized
Randomization description
Using the balanced block randomization method. Random division is done in the form of "blocks" of predetermined size. For example, if the size of block is 6, the operation of random division until the third one person is randomly assigned to one group, and then individuals are automatically assigned to another group until a 6-piece block is completed. The features of this method are that it is easy to implement and balance in the number of groups is guaranteed.
Blinding (investigator's opinion)
Double blinded
Blinding description
In this study, in addition to the patient, health care personnel, data collectors, and those evaluating the outcome are blinded.
Placebo
Used
Assignment
Parallel
Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee
Name of ethics committee
Research Ethics Committee of Iran University of Medical Sciences
Street address
Shahid Hemmat Highway next to Milad Tower, Tehran
City
Tehran
Province
Tehran
Postal code
۱۴۴۹۶۱۴۵۳۵
Approval date
2022-02-04, 1400/11/15
Ethics committee reference number
IR.IUMS.REC.1400.1061

Health conditions studied

1

Description of health condition studied
Benign Prostatic Hypertrophy
ICD-10 code
N40.1
ICD-10 code description
Enlarged prostate with lower urinary tract symptoms

2

Description of health condition studied
Lower Urinary Tract Symptoms
ICD-10 code
N40.1
ICD-10 code description
Enlarged prostate with lower urinary tract symptoms

Primary outcomes

1

Description
تغییرات امتیاز بین اللملی علائم پروستات
Timepoint
Before the intervention and 2 weeks after the intervention
Method of measurement
Questionnaire

2

Description
Q max
Timepoint
Before the intervention and 2 weeks after the intervention
Method of measurement
Euroflowmetry

3

Description
Prostate volume
Timepoint
Before the intervention and 2 weeks after the intervention
Method of measurement
Sonography

Secondary outcomes

1

Description
Prostate specific antigen (PSA)
Timepoint
Before the intervention and 2 weeks after the intervention
Method of measurement
ELISA test

2

Description
Drug side effects
Timepoint
During the study and two weeks after the study
Method of measurement
Questionnaire

Intervention groups

1

Description
Intervention group: Will received Tamsulosin (0.4 mg per night, 1 piece) with Cucumis melo L seeds 500 mg oral capsule three times daily after each meal for up to 6 weeks. The medicine is made by a pharmacist.
Category
Treatment - Drugs

2

Description
Control group: The control group received Tamsulosin (0.4 mg 1 per night) with placebo oral capsules (500 mg of starch) three times daily after each meal for up to 6 weeks.
Category
Treatment - Drugs

Recruitment centers

1

Recruitment center
Name of recruitment center
Hasheminejad Kidney Center
Full name of responsible person
Dr. Pejman Shadpour
Street address
Vali-nejad Str., Vanak Sq. Vali-e-asr Boul, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
۱۹۶۹۷۱۴۷۱۳
Phone
+98 21 81161
Email
info@iums.ac.ir

Sponsors / Funding sources

1

Sponsor
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Dr. Hossein Kiwani
Street address
Shahid Hemmat Highway ,Tehran
City
Tehran
Province
Tehran
Postal code
۱۴۴۹۶۱۴۵۳۵
Phone
+98 21 8670 2503
Email
research-m@iums.ac.ir
Grant name
Grant code / Reference number
Is the source of funding the same sponsor organization/entity?
No
Title of funding source
Health Management Research Institute
Proportion provided by this source
100
Public or private sector
Public
Domestic or foreign origin
Domestic
Category of foreign source of funding
empty
Country of origin
Type of organization providing the funding
Academic

Person responsible for general inquiries

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Dr. Pejman Shadpour
Position
professor
Latest degree
Subspecialist
Other areas of specialty/work
Urology
Street address
Vali-nejad Str., Vanak Sq. Vali-e-asr Boul, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
۱۹۶۹۷۱۴۷۱۳
Phone
+98 21 81161
Email
pshadpour@gmail.com

Person responsible for scientific inquiries

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Dr. Pejman Shadpour
Position
professor
Latest degree
Subspecialist
Other areas of specialty/work
Urology
Street address
Hasheminejd Kidney Center, Vali-nejad Str., Vanak Sq. Vali-e-asr Boul, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
۱۹۶۹۷۱۴۷۱۳
Phone
+98 21 81161
Email
pshadpour@gmail.com

Person responsible for updating data

Contact
Name of organization / entity
Iran University of Medical Sciences
Full name of responsible person
Atefe Sharif
Position
Non-faculty specialist physician
Latest degree
Ph.D.
Other areas of specialty/work
Traditional Medicine
Street address
Hasheminejd Kidney Center, Vali-nejad Str., Vanak Sq. Vali-e-asr Boul, Tehran, Iran
City
Tehran
Province
Tehran
Postal code
۱۹۶۹۷۱۴۷۱۳
Phone
+98 21 81161
Email
atf.sharif@sbmu.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)
No - There is not a plan to make this available
Justification/reason for indecision/not sharing IPD
محرمانه بودن
Study Protocol
No - There is not a plan to make this available
Statistical Analysis Plan
No - There is not a plan to make this available
Informed Consent Form
No - There is not a plan to make this available
Clinical Study Report
No - There is not a plan to make this available
Analytic Code
No - There is not a plan to make this available
Data Dictionary
No - There is not a plan to make this available
Loading...